Model-based decision-making approach published in „BLOOD“

In January 2020 the internationally leading haematology journal "BLOOD" published a biometric analysis of clinical trial data on chronic myeloid leukaemia (CML), which was designed and performed at the IMB. While standard therapy with tyrosine kinase inhibitors (TKI) leads to a complete remission in almost all CML patients, this remission can only be maintained in about 50% of patients after TKI discontinuation. Based on data from a clinical trial coordinated in Liverpool (UK), it could be shown that the patient-specific response to TKI dose reduction provides information on whether or not a subsequent complete cessation of the TKI therapy is associated with a high risk of relapse for the respective patient. These results may contribute to improve patient-specific predictions, as to whether or not complete discontinuation of therapy is appropriate and justifiable, or whether the patient is more likely to benefit from dose reduction, which is also associated with a reduction in therapy side effects. 

Link to publication: 
https://dx.doi.org/10.1182/blood.2019003395